Heptares Therapeutics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Heptares Therapeutics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH194521D
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Heptares Therapeutics Ltd (Heptares), a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs. The company develops drugs for targeting G-protein-coupled receptors by utilizing its drug discovery technology platforms. Its technology platforms comprise StaR technology, StaR-driven X-ray crystallography, Biophysical Mapping and StaR fragment screening. Heptares' products are used in the treatment of Alzheimer's disease, schizophrenia, binge eating, type 2 diabetes, autism, depression, dyskinesia, migraine treatment, and others. The company partners with other pharma and biotech companies to develop its products. Heptares is headquartered in Welwyn Garden, the UK.

Heptares Therapeutics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Heptares Therapeutics Raises US$21 Million In Series B Financing 12

Partnerships 13

Heptares Therapeutics Enters into Research Agreement with University of Cambridge 13

Jitsubo Enters into Agreement with Heptares Therapeutics 13

Heptares Therapeutics and leadXpro Enter into Agreement 14

Heptares Therapeutics to Form Partnership with Kymab 15

Heptares Therapeutics Enters into Agreement with Pfizer 16

MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 17

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 18

ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 19

AstraZeneca Enters Into Co-Development Agreement With Heptares 19

Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 20

Licensing Agreements 22

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 22

Allergan Enters into Licensing Agreement with Heptares Therapeutics 23

Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 24

AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 25

Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 26

Acquisition 27

Heptares Therapeutics to Acquire G7 Therapeutics for USD11.83 Million 27

Sosei Acquires Heptares Therapeutics for USD400 Million 28

Heptares Therapeutics Ltd-Key Competitors 30

Key Employees 31

Locations And Subsidiaries 32

Head Office 32

Recent Developments 33

Government and Public Interest 33

Dec 08, 2016: Heptares Scientists Solve Structure of CCR9 Chemokine Receptor Offering Unique Opportunity to Apply Structure-Based Design Across Chemokine Receptor Family 33

Dec 08, 2016: Sosei subsidiary Heptares scientists solve structure of CCR9 Chemokine receptor offering unique opportunity to apply structurebased design across Chemokine receptor 34

Apr 25, 2016: Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-based Design for Metabolic Disease 35

Jan 11, 2016: Tetragenetics Awarded $1.5M Research and Development Grant by NIH 36

Clinical Trials 37

Jul 06, 2016: Initiation of Phase 1 Clinical Study With Novel Immuno-oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca 37

Feb 10, 2016: Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia 38

Other Significant Developments 39

Feb 02, 2016: Heptares Launches "Orbit" Initiative-A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS) 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40

List of Figures

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Heptares Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Heptares Therapeutics Raises US$21 Million In Series B Financing 12

Heptares Therapeutics Enters into Research Agreement with University of Cambridge 13

Jitsubo Enters into Agreement with Heptares Therapeutics 13

Heptares Therapeutics and leadXpro Enter into Agreement 14

Heptares Therapeutics to Form Partnership with Kymab 15

Heptares Therapeutics Enters into Agreement with Pfizer 16

MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 17

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 18

ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 19

AstraZeneca Enters Into Co-Development Agreement With Heptares 19

Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 20

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 22

Allergan Enters into Licensing Agreement with Heptares Therapeutics 23

Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 24

AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 25

Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 26

Heptares Therapeutics to Acquire G7 Therapeutics for USD11.83 Million 27

Sosei Acquires Heptares Therapeutics for USD400 Million 28

Heptares Therapeutics Ltd, Key Competitors 30

Heptares Therapeutics Ltd, Key Employees 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Heptares Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16225
Site License
USD 500 INR 32450
Corporate User License
USD 750 INR 48675

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com